These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.
- EXAS, +0.98% gained more than 7% in premarket trading Wednesday after the company released results from a study of its next-generation Cologuard, a non-invasive colorect…
- Exact Sciences’s Q3 earnings are confirmed for Thursday, November 2, 2023.
- Exact Sciences’ stock is owned by a variety of retail and institutional investors.
Data may be intentionally delayed pursuant to supplier requirements. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Style is an investment factor that has a meaningful impact on investment risk and returns.
69.0% of employees surveyed would recommend working at Exact Sciences to a friend. Shares of Guardant Health Inc. tanked 40% and shares of Exact Sciences Corp. rallied more than 25% in the extended session Thursday after Guardant announced results from a study using its blood test to screen for colorec… Product offerings and availability vary based on jurisdiction. When you see EXAS stock appear in the results, tap it to open up the purchase screen. Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.
Please see Open to the Public Investing’s Fee Schedule to learn more. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.
TipRanks reveals the top 10 health care sector analysts of the past decade
Reports record results, raises full-year guidance, accelerates path to positive free cash flow First quarter highlights Total first quarter revenue of $602 million, an increase of 24%, and $598 milli… BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial and ethnic diversity of the U.S. Kevin Conroy, Exact Sciences CEO, joins ‘Fast Money’ to discuss Exact Sciences latest trial results for its colo-rectal cancer tests, Cologuard.
328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company’s employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
- They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.
- A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
- These returns cover a period from January 1, 1988 through July 31, 2023.
- This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.
- Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.
EXAS, +0.98% gained more than 7% in premarket trading Wednesday after the company released results from a study of its next-generation Cologuard, a non-invasive colorect… Exact Sciences’ stock is owned by a variety of retail and institutional investors. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
Exact Sciences started at neutral with $73 stock price target at UBS
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual esports stocks securities. Exact Sciences’ stock was trading at $49.51 at the beginning of 2023. Since then, EXAS shares have increased by 58.7% and is now trading at $78.59. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.
Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
This site is protected by reCAPTCHA and the Google
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. Compare
EXAS’s historical performance
against its industry peers and the overall market.
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).
Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million, an increase of 19%, and $617 million … Upgrade to MarketBeat All Access to add more https://bigbostrade.com/ stocks to your watchlist. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Stocks, 1 Potentially Explosive Growth Theme
The consensus among Wall Street research analysts is that investors should “moderate buy” EXAS shares. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.
These stock pickers led the health-fund category over the past 5 years. Here’s where they’re investing now.
They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. 14 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Exact Sciences in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. The table below shows EXAS’s growth in key financial areas (numbers in millions of US dollars). Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. EXAS’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Morningstar analysts hand-select direct competitors or comparable companies to
provide context on the strength and durability of EXAS’s
competitive advantage. Exact Sciences’ approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program anal… One share of EXAS stock can currently be purchased for approximately $78.59.